Phase I/II clinical trials using hepatitis C virus peptide with the combination therapy of interferon and ribavirin for the patient with chronic hepatitis C
Phase 1
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000002601
- Lead Sponsor
- Ehime University Graduate School of Medicine, Department of Gastroenterology and Metabology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
The patient who has allergy for interferon or ribavirin or other vaccines. Pregnant patients. The patients with autoimmune diseases. The patients with depression. The patients with diabetes mellitus and hypertension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ratio of sustained viral response for hepatitis C virus, the ratio of rapid viral response for hepatitis C virus, the ratio of early viral response for hepatitis C virus.
- Secondary Outcome Measures
Name Time Method The frequency of adverse events.